Pyxis Oncology, an immuno-oncology company developing antibody drugs to restore activity to dysfunctional T cells, has appointed Ronald Herbst as its chief scientific officer. Herbst joins the Boston-based company from the AstraZeneca (NYSE: AZN) global biologics R&D arm, MedImmune, where he was vice president of research and development and head of oncology research.
Sponsored · Whitepaper
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems
From Our Partners · Special Report
Advice for funding and future transformational opportunities
Sponsored · Webinar
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Eurofins Discovery
